Type 2 Diabetes and Dementia 2018
DOI: 10.1016/b978-0-12-809454-9.00009-3
|View full text |Cite
|
Sign up to set email alerts
|

Advanced Glycation, Diabetes, and Dementia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 152 publications
0
7
0
Order By: Relevance
“… 15 Diabetes is one of the risk factors for developing dementia as reported in the literature, with increases in glycated haemoglobin, thus creating a greater risk of developing diabetes complications; therefore, diabetes control is an important preventive measure for better cognitive function. 16 …”
Section: Discussionmentioning
confidence: 99%
“… 15 Diabetes is one of the risk factors for developing dementia as reported in the literature, with increases in glycated haemoglobin, thus creating a greater risk of developing diabetes complications; therefore, diabetes control is an important preventive measure for better cognitive function. 16 …”
Section: Discussionmentioning
confidence: 99%
“…AGEs can directly damage vessel walls and interact with receptors throughout the body (e.g. receptors for AGEs: RAGEs), including neurons and glia in the brain, to increase oxidative stress and inflammation (Dhananjayan et al, 2018). Thus, AGEs may not only negatively affect the vasculature but also impact neural health, possibly facilitating neuronal degeneration and apoptosis (Juranek et al, 2015).…”
Section: Discussionmentioning
confidence: 99%
“…Thus, AGEs may not only negatively affect the vasculature but also impact neural health, possibly facilitating neuronal degeneration and apoptosis (Juranek et al, 2015). Cross-sectional studies have provided initial evidence of an association of increased peripheral AGEs to cognitive impairment and lower grey matter volume in older adults with diabetes (Dhananjayan et al, 2018). Although type 2 diabetes has been found to increase risk for Alzheimer's clinical syndrome, the pathological hallmarks of Alzheimer's disease (i.e.…”
Section: Discussionmentioning
confidence: 99%
“…Azeliragon, a novel drug, has been reported to decrease amyloid deposition and brain inflammation by antagonizing the AGE receptor[ 206 , 207 ]. Based on the preliminary results from a phase III 18-month clinical trial in AD patients, the use of azeliragon decreased pro-inflammatory markers, hippocampus atrophy, and cognitive deterioration.…”
Section: New Strategies For the Treatment Of Admentioning
confidence: 99%